TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06816121: Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

Sponsor: Everest Detection, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06816121 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06816121 Rescue Dossier →